LONDON, February 17, 2015 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Investor-Edge has initiated coverage on the following equities: Exelixis Inc. (NASDAQ: EXEL), Exact Sciences Corporation (NASDAQ: EXAS), Idera Pharmaceuticals Inc. (NASDAQ: IRDA), Seattle Genetics Inc. (NASDAQ: SGEN), and Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD). Free research report on Exelixis can be accessed at http://get.Investor-Edge.com/pdf/?c=Exelixis&d=17-Feb-2015&s=EXEL. The US markets on Friday, February 13, 2015, ended on a positive note as the Dow Jones Industrial Average finished at 18,019.35, up 0.26% and the NASDAQ Composite closed at 4,893.84, up 0.75%. The S&P 500 finished the session 0.41% higher at 2,096.99. During the trading session, six out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 817.78, up 0.51%, with the index advancing 5.21% in the previous three months. Register for your complimentary reports at the links given below.

Exelixis Inc.'s stock rallied 8.77%, to close the day at $2.48. The stock recorded a trading volume of 7.20 million shares, above its three months average volume of 3.05 million shares. The company's shares oscillated between $2.25 and $2.52 during the session. Over the last three trading sessions and over the past one month, Exelixis Inc.'s shares have rallied 13.24% and 49.40%, respectively. Further, the stock has surged 43.35% in the previous three months. The stock is trading above its 50-day moving average of $1.64, while the 50-day moving average is below Exelixis Inc.'s 200-day moving average of $2.52. Additionally, the stock has a Relative Strength Index (RSI) of 76.80. Sign up and read the free notes on EXEL at:

http://get.Investor-Edge.com/pdf/?c=Exelixis&d=17-Feb-2015&s=EXEL

On Friday, shares in Exact Sciences Corp. recorded a trading volume of 1.39 million shares, lower than its three months average volume of 1.48 million shares. The stock ended the day at $25.56, which was 2.07% below its previous day's closing of $26.10, and registered an intraday range of $25.12 and $26.25. Exact Sciences Corp.'s shares have lost 3.03% in the previous three trading sessions, while the stock has gained 11.13% in the last three months and 108.65% in the past one year. The stock is trading above its 200-day moving average of $20.73, which is below the stocks' 50-day moving average of $27.33. Furthermore, shares of Exact Sciences Corp. have an RSI of 40.80. The complimentary notes on EXAS can be downloaded as in PDF format at:

http://get.Investor-Edge.com/pdf/?c=Exact%20Sciences&d=17-Feb-2015&s=EXAS

Idera Pharmaceuticals Inc.'s stock fell 3.30% to end Friday's session at $4.10. The stock recorded a trading volume of 11.04 million shares, much above its three months average volume of 2.20 million shares. The company's shares fluctuated between $3.88 and $4.13 during the session. Idera Pharmaceuticals Inc.'s shares have lost 12.58% over the last one month. However, the stock has advanced 2.24% in the previous three trading sessions and 67.35% in the past three months. The stock is trading above its 200-day moving average. Idera Pharmaceuticals Inc.'s 50-day moving average of $4.37 is above its 200-day moving average of $3.09. Additionally, the stock has an RSI of 43.92. Register for free on Investor-Edge and access the latest research on IDRA at:

http://get.Investor-Edge.com/pdf/?c=Idera%20Pharma&d=17-Feb-2015&s=IDRA

On Friday, shares in Seattle Genetics Inc. fluctuated between $31.17 and $31.74 before ending the session 1.15% higher at $31.57. The stock reported a trading volume of 1.03 million shares, lower than its three months average volume of 1.29 million shares. Seattle Genetics Inc.'s stock has lost 2.71% in the previous three trading sessions, 10.72% in the last three months, and 37.01% in the past one year. The stock is trading below its 50-day and 200-day moving averages of $32.40 and $36.25, respectively. Moreover, shares of Seattle Genetics Inc. have an RSI of 46.99. The complete research on SGEN is available for free at:

http://get.Investor-Edge.com/pdf/?c=Seattle%20Genetics&d=17-Feb-2015&s=SGEN

Ironwood Pharmaceuticals Inc.'s stock finished Friday's session 5.31% lower at $15.15. A total of 1.76 million shares were traded, which was above its three months average volume of 0.85 million shares. The stock vacillated between $14.87 and $15.84 during the session. Over the previous three months and over the past one year, Ironwood Pharmaceuticals Inc.'s shares have gained 15.38% and 9.78%, respectively. However, over the last one month, the stock has fallen by 3.63%. The company's shares are trading above their 200-day moving average. Moreover, the stock's 50-day moving average of $15.19 is greater than its 200-day moving average of $14.01. Ironwood Pharmaceuticals Inc.'s stock has an RSI of 46.03. On February 12, 2015, Ironwood Pharmaceuticals Inc. announced its Q4 FY14 and full-year FY14 financial results (period ended December 31, 2014). For Q4 FY14, the company reported net loss of $37.65 million, or $0.27 per diluted share. For FY14, the company reported net loss of $189.62 million, or $1.39 per diluted share. Free in depth research on IRWD is available at:

http://get.Investor-Edge.com/pdf/?c=Ironwood%20Pharma&d=17-Feb-2015&s=IRWD

About Investor-Edge.com

At Investor-Edge, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Investor-Edge comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.

===============

EDITOR'S NOTES:

===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.investor-edge.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.investor-edge.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.investor-edge.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-Edge, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Investor-Edge in this article or report according to the procedures outlined by Investor-Edge. Investor-Edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Investor-Edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Investor-Edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-Edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-Edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-Edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA(R) and Chartered Financial Analyst(R) are registered trademarks owned by CFA Institute.

SOURCE Investor-Edge